首页>投融资
Evommune
C轮
Evommune, founded in 2020 by former senior leaders at Dermira, is using a tissue-based screening platform to identify molecules and compounds for the potential treatment of immune-mediated and chronic inflammatory diseases.The company is headquartered in Los Altos, California.In June 2023, Evommune Inc closed an additional $7.5 million to its Series B financing.In April 2023, Evommune Inc completed a $50 million Series B financing, led by its investors.In September 2021, the company announced the completion of USD 83 million Series A financing which included Andera Partners and LSP, together with a global syndicate of investors and existing investor Pivotal bioVenture Partners
基本信息
-
公司全称Evommune Inc
-
类型生物新药研发商
-
产业领域药品研发/制造、医药研发/制造、生物药、化学药
-
公司人数15人以下
-
地址1625 N. Market Blvd., Suite N-112 SACRAMENTO CALIFORNIA 95834; US; Telephone: +18009525210;
-
联系电话
-
邮箱
-
成立时间2020-01-01
投融资
-
2024-10-31C轮1.15亿美元RA CapitalSectoral Asset Management波士顿投资Marshall WaceAvego Bioscience CapitalLongwood FundRTW InvestmentsADAR1 Capital ManagementFemHealth VenturesAllostery InvestmentsPivotal bioVenture PartnersEQT PartnersAndera PartnersAmplitude Venture CapitalSymbiosisVerition Fund Management
-
2023-06-28B轮750万美元Verition Fund Management
-
2023-04-26B轮5000万美元Andera PartnersAmplitude Venture CapitalEQT PartnersSymbiosisArix BiosciencePivotal bioVenture Partners
-
2021-09-09A轮8300万美元Pivotal bioVenture PartnersLife Sciences PartnersAndera Partners
-
2020-11-18种子轮1250万美元Pivotal bioVenture Partners
- 加载更多
相关投融资企业
收并购
Advanced Accelerator Applications (AAA), a subsidiary of Novartis AG, founded in 2002 by Italian academics as a spin-off from the European Organization for Nuclear Research (CERN, Switzerland), develops diagnostic and therapeutic products, including PET radiopharmaceuticals. The company focuses on Personalized Medicine, aimed at providing treatments tailored to a patient's profile and disease, using predictive, preventive and personalized procedures. In January 2018, AAA became a subsidiary of Novartis AG.In July 2016, the company opened its first US manufacturing facility in Millburn, NJ. The Millburn plant served as a distribution center for NETSPOT.In April 2014, AAA opened a new office in the US located at Manhattan, NY. At that time, the company planned to set up a new manufacturing facility in the US.In February 2012, AAA planned to build a radiopharmaceutical facility in Murcia, Spain. The facility was expected to be completed within 18 months.By December 201
B轮
Veradermics Inc (美国)：Veradermics是一家位于美国的生物技术公司，专注于皮肤健康和美容产品的研发。公司的主要研究领域包括皮肤再生、抗衰老和皮肤修复。Veradermics利用其专有的生物材料和技术平台，开发了一系列高效的皮肤护理产品。公司的产品线包括抗衰老面霜、皮肤修复凝胶和皮肤再生面膜等。
B轮
Qnovia, formerly known as Respira Technologies, is focused on developing inhaled drug delivery platforms to deliver drugs for nicotine replacement therapy and cardiopulmonary diseases.In September 2022, the company changed its name from Respira Technologies to Qnovia.In September 2022, the company raised USD 17M in Series A funding led by Blue Ledge Capital, DG Ventures, Evolution VC Partners, Gaingels, TL Capital, and Vice Ventures,
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息